Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс:
http://elar.urfu.ru/handle/10995/131238
Название: | Triazavirin—A Novel Effective Antiviral Drug |
Авторы: | Chupakhin, O. N. Rusinov, V. L. Varaksin, M. V. Ulomskiy, E. N. Savateev, K. V. Butorin, I. I. Du, W. Sun, Z. Charushin, V. N. |
Дата публикации: | 2022 |
Издатель: | MDPI |
Библиографическое описание: | Chupakhin, ON, Rusinov, VL, Varaksin, MV, Ulomskiy, EN, Savateev, KV, Butorin, II, Du, W, Sun, Z & Charushin, VN 2022, 'Triazavirin—A Novel Effective Antiviral Drug', International Journal of Molecular Sciences, Том. 23, № 23, 14537. https://doi.org/10.3390/ijms232314537 Chupakhin, O. N., Rusinov, V. L., Varaksin, M. V., Ulomskiy, E. N., Savateev, K. V., Butorin, I. I., Du, W., Sun, Z., & Charushin, V. N. (2022). Triazavirin—A Novel Effective Antiviral Drug. International Journal of Molecular Sciences, 23(23), [14537]. https://doi.org/10.3390/ijms232314537 |
Аннотация: | This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug. © 2022 by the authors. |
Ключевые слова: | ANTIVIRAL THERAPY COVID-19 RIAMILOVIR SARS-COV-2 TRIAZAVIRIN ANIMALS ANTIVIRAL AGENTS AZOLES COVID-19 ENCEPHALITIS, TICK-BORNE HUMANS INFLUENZA, HUMAN OSELTAMIVIR OXYGEN RADICAL RIAMILOVIR ANTIVIRUS AGENT PYRROLE DERIVATIVE AIRWAY EPITHELIUM CELL ALKYLATION ANTIMICROBIAL ACTIVITY ANTINEOPLASTIC ACTIVITY ANTIVIRAL ACTIVITY ANTIVIRAL THERAPY BILIRUBIN BLOOD LEVEL BIOLOGICAL FUNCTIONS CHEMICAL REACTION CLINICAL PRACTICE COMPARATIVE STUDY CORONAVIRUS DISEASE 2019 DISSOCIATION CONSTANT DRUG BIOAVAILABILITY DRUG EFFICACY ELIMINATION HALF-LIFE HUMAN HYDROGEN BOND INFLUENZA A VIRUS (H7N3) INFLUENZA A VIRUS (H9N2) INFLUENZA VIRUS KIDNEY FUNCTION LUNG PARENCHYMA MOLECULAR MODEL NITROSYLATION NONHUMAN OXIDATIVE STRESS OXYGEN BREATHING POLYMERASE CHAIN REACTION REACTION TEMPERATURE REGIOSELECTIVITY REVIEW RIFT VALLEY FEVER RING OPENING ROOM TEMPERATURE RUSSIAN FEDERATION STATIC ELECTRICITY STEREOSPECIFICITY SUBSTITUTION REACTION TAUTOMER TICK BORNE ENCEPHALITIS TICK BORNE ENCEPHALITIS VIRUS VIRUS REPLICATION WEST NILE FEVER X RAY CRYSTALLOGRAPHY ANIMAL INFLUENZA TICK BORNE ENCEPHALITIS |
URI: | http://elar.urfu.ru/handle/10995/131238 |
Условия доступа: | info:eu-repo/semantics/openAccess cc-by |
Текст лицензии: | https://creativecommons.org/licenses/by/4.0/ |
Идентификатор SCOPUS: | 85143736704 |
Идентификатор WOS: | 000897437000001 |
Идентификатор PURE: | 32888400 a2205dfe-145a-485a-b788-c0f8bd695a31 |
ISSN: | 1661-6596 |
DOI: | 10.3390/ijms232314537 |
Сведения о поддержке: | National Natural Science Foundation of China, NSFC, (20-53-55003, 82161148007) Russian Foundation for Basic Research, РФФИ Ministry of Education and Science of the Russian Federation, Minobrnauka, (FEUZ-2022-0001) This work was supported by the Ministry of Science and Higher Education of the Russian Federation (Project No FEUZ-2022-0001), RFBR and NSFC (RFBR project No 20-53-55003, NSFC project number No 82161148007). |
Располагается в коллекциях: | Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC |
Файлы этого ресурса:
Файл | Описание | Размер | Формат | |
---|---|---|---|---|
2-s2.0-85143736704.pdf | 8,35 MB | Adobe PDF | Просмотреть/Открыть |
Лицензия на ресурс: Лицензия Creative Commons